

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12168 A2

(51) International Patent Classification⁷: **A61K 31/00**

[NL/NL]: Johan Buziaulaan 41, NL-3584 ZT Utrecht (NL).

(21) International Application Number: **PCT/NL00/00559**

(74) Agent: **KUPECZ, Arpad**: Octrooibureau Los en Stigter B.V., Weteringschans 96, NL-1017 XS Amsterdam (NL).

(22) International Filing Date: **9 August 2000 (09.08.2000)**

(25) Filing Language: **Dutch**

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: **English**

(30) Priority Data:
1012825 13 August 1999 (13.08.1999) NL

(71) Applicant (*for all designated States except US*): **FACULTEIT GENEESKUNDE UNIVERSITEIT UTRECHT** [NL/NL]; Universiteitsweg 100, P.O. Box 80030, NL-3508 TA Utrecht (NL).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **VAN ASBECK, Bernt, Sweder** [NL/NL]; Verheullaan 19, NL-3971 RD Driebergen (NL). **MARX, Johannes, Josephus, Maria**

Published:

— Without international search report and to be republished upon receipt of that report.

[Continued on next page]

(54) Title: **PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF VIRAL INFECTIONS, IN PARTICULAR OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV)**



(57) Abstract: The invention describes a pharmaceutical product for the treatment of viral infections, in particular of the human immunodeficiency virus (HIV). According to the invention, the pharmaceutical product comprises a compound that as active component contains an iron chelator. Suitable iron chelators are selected from the group of hydroxamates (such as deferoxamine), the family of the hydroxypyridinons (such as deferiprone), and the nucleic acid-binding chemotherapeutical products (such as bleomycine). A synergistic effect is obtained in vitro when in addition to the component containing the iron chelator, a product is used that contains another virus-inhibiting compound. As the antiviral agent a protease-inhibitor, preferably ritonavir, is considered. Another suitable antiviral agent is a reverse transcriptase inhibitor, preferably a dideoxyinosine.

WO 01/12168 A2